Use of SGLT2i in noHCM With HFpEF

Sponsor
China National Center for Cardiovascular Diseases
Study ID
NCT06401343
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.

Study Details

This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.

Key Dates

Start date
Aug 1, 2022
Status verified
May 2024
Primary completion
Aug 1, 2024
Completion
Aug 1, 2025

Study Design

Enrollment
94 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Study group
    Use of Empagliflozin+guideline directed medical treatment of HCM
  • No Intervention: Control group
    Guideline directed medical treatment of HCM

Primary Outcome Measure

VO2max on cardiopulmonary exercise tesing [ Time Frame: 12 months ]

Related Studies